Fate Therapeutics CEO J Wolchko's 2021 pay jumps 109% to $12M
Fate Therapeutics reports 2021 executive compensation
By ExecPay News
Published: April 25, 2022
Fate Therapeutics reported fiscal year 2021 executive compensation information on April 25, 2022.
In 2021, six executives at Fate Therapeutics received on average a compensation package of $7.7M, a 105% increase compared to previous year.
Average pay of disclosed executives at Fate Therapeutics
J. Scott Wolchko, Chief Executive Officer, received $12M in total, which increased by 109% compared to 2020. 81% of Wolchko's compensation, or $9.6M, was in stock awards. Wolchko also received $366K in non-equity incentive plan, $1.2M in option awards, as well as $610K in salary.
Mark Plavsic, Chief Technology Officer, received a compensation package of $8.4M. 83% of the compensation package, or $6.9M, was in stock awards.
Bahram Valamehr, Chief Research and Development Officer, earned $6.5M in 2021, a 163% increase compared to previous year.
Cindy R. Tahl, General Counsel, received $6.5M in 2021, which increases by 163% compared to 2020.
Yu-Waye Chu, Chief Medical Officer, earned $6.5M in 2021.
Edward J. Dulac III, Chief Financial Officer, received $6.4M in 2021, which increases by 12% compared to 2020.
Related executives
J Wolchko
Fate Therapeutics
Chief Executive Officer
Edward Dulac
Fate Therapeutics
Chief Financial Officer
Bahram Valamehr
Fate Therapeutics
Chief Research and Development Officer
Cindy Tahl
Fate Therapeutics
General Counsel
Yu-Waye Chu
Fate Therapeutics
Chief Medical Officer
Mark Plavsic
Fate Therapeutics
Chief Technology Officer
You may also like
Source: SEC filing on April 25, 2022.